摘要
目的:观察重组人血管内皮抑制素联合放化疗用于非小细胞肺癌(NSCLC)患者的效果。方法:选取2018年4月至2021年4月该院收治的64例NSCLC患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各32例。对照组采用放化疗,观察组在对照组基础上联合重组人血管内皮抑制素治疗,比较两组肿瘤控制率,治疗前后血清学指标[癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、异常糖链糖蛋白(TAP)]水平、生命质量[癌症患者生命质量量表(FACT-G)]评分、治疗期间不良反应发生率,以及6、9、12个月生存率。结果:观察组肿瘤控制率为71.88%(23/32),高于对照组的43.75%(14/32),差异有统计学意义(P<0.05);治疗后,观察组血清CEA、NSE和血浆TAP水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组生理状况、情感状况等FACT-G评分均低于对照组,社会/家庭情况、功能状况评分均高于对照组,差异有统计学意义(P<0.05);两组发热、粒细胞减少、放射性肺炎、放射性食管炎、胃肠道反应和放射性心肌损伤等不良反应发生率比较,差异均无统计学意义(P>0.05);观察组6、9、12个月生存率均高于对照组,差异有统计学意义(P<0.05)。结论:重组人血管内皮抑制素联合放化疗用于NSCLC患者可提高肿瘤控制率和生存率,降低血清学指标水平,改善生命质量评分,效果优于单纯放化疗。
Objective:To observe effects of recombinant human endostatin combined with chemoradiotherapy on patients with non-small cell lung cancer(NSCLC).Methods:A prospective study was conducted on 64 patients with NSCLC admitted to the hospital from April 2018 to April 2021.They were divided into control group and observation group according to the random number table method,32 patients in each group.The control group was treated with chemoradiotherapy,while the observation group was treated with recombinant human endostatin on the basis of that of the control group.The clinical tumor control rate,the serology indicator levels[carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),tumor abnormal protein(TAP)],the quality of life[functional assessment of cancer therapy(FACT-G)]score,the incidence of adverse reactions during the treatment,and the 6,9,12-month survival rate were compared between the two groups.Results:The tumor control rate in the observation group was 71.88%(23/32),which was higher than 43.75%(14/32)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of serum CEA,NSE and plasma TAP in the observation group were significantly lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the FACT-G scores of physiological and emotional conditions in the observation group were lower than those in the control group;the scores of social/family status and functional status in the observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions such as fever,granulocytopenia,radiation pneumonitis,radiation esophagitis,gastrointestinal reaction and radiation myocardial injury between the two groups(P>0.05).The 6-month,9-month and 12-month survival rates in the observation group were significantly higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusions:Recombinant human endostatin combined with chemoradiotherapy can improve the tumor control rates and the survival rates of the NSCLC patients,reduce the levels of serological indicators,and improve the quality of life score.Moreover,it is superior to single chemoradiotherapy.
作者
张潇
ZHANG Xiao(Chemoradiotherapy Department of the Central Hospital of Jiamusi City,Jiamusi 154002 Heilongjiang,China)
出处
《中国民康医学》
2023年第5期38-41,共4页
Medical Journal of Chinese People’s Health
关键词
放化疗
重组人血管内皮抑制素
非小细胞肺癌
癌胚抗原
肿瘤异常糖链糖蛋白
生命质量
生存率
Chemoradiotherapy
Recombinant human endostatin
Non-small cell lung cancer
Carcinoembryonic antigen
Tumor abnormal protein
Quality of life
Survival rate
作者简介
张潇(1984.05-),男,汉族,黑龙江佳木斯人,硕士研究生,主治医师,研究方向为肿瘤放射治疗。
